TriOptima Successfully Compress Swedish Krona Rate Swaps in Nasdaq

The service eliminated 40 percent of Nasdaq's outstanding swap inventory.

candle-charts

TriOptima, through its multilateral portfolio compression service triReduce, was able to eliminate 40 percent of Nasdaq members' cleared outstanding Swedish Krona swap inventory.

The infrastructure streamlines portfolios, reduces systemic risk, and helps to adhere to certain Basel III requirements, said Peter Weibel, triReduce chief executive officer, in a statement. 

"With the new capital requirements under Basel III, banks and clearing brokers need to look for additional ways to reduce exposures as well as notional outstanding on their balance sheets," said Johan Ruden, senior vice president and head of Nordic fixed income at Nasdaq, in a statement.

The company said triReduce has helped OTC derivative market participants drop $768 trillion in notional principal through March 2016.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

If M&A picks up, who’s on the auction block?

Waters Wrap: With projections that mergers and acquisitions are geared to pick back up in 2025, Anthony reads the tea leaves of 25 of this year’s deals to predict which vendors might be most valuable.

Removal of Chevron spells t-r-o-u-b-l-e for the C-A-T

Citadel Securities and the American Securities Association are suing the SEC to limit the Consolidated Audit Trail, and their case may be aided by the removal of a key piece of the agency’s legislative power earlier this year.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here